Can a simple drug make urethral surgery safer?

NCT ID NCT07501884

Not yet recruiting Disease control Sponsor: Amjad Alwaal, MD, MSc, FRCSC, FACS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether a single dose of tranexamic acid (TXA), a drug that helps blood clot, can reduce blood loss during urethral reconstruction surgery. Forty adults having this surgery will be randomly assigned to receive TXA or standard care. Researchers will compare changes in hemoglobin levels and other bleeding-related outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tranexamic acid (TXA)
What this could lead to: If it works, this could lead to a simple, safe way to reduce blood loss during urethral surgery, potentially improving recovery and reducing complications.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. TXA also carries a small risk of blood clots, though participants with clotting history are excluded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URETHRAL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage urethral disorder urethral stricture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URETHRAL DISEASES URETHRAL STRICTURE

Contacts and locations

Locations

University Hospital

Newark, New Jersey, 07103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.